Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 1, 2009, Pages 53-59

  Kitagawa, Jun Ichi ^a   Hara, Takeshi ^a   Tsurumi, Hisashi ^a   Goto, Naoe ^a   Kanemura, Nobuhiro ^a   Yoshikawa, Takeshi ^b   Kasahara, Senji ^a   Yamada, Toshiki ^a   Sawada, Michio ^a   Takahashi, Takeshi ^b   Shimizu, Masahito ^a   Takami, Tsuyoshi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Gifu Municipal Hospital   (Japan)

Author keywords

Peripheral T cell lymphoma (PTCL); Prognostic analysis; Soluble interleukin 2 receptor (sIL 2R)

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PIRARUBICIN; PREDNISOLONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE CLASSIFICATION; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; NEUTROPENIA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; T LYMPHOCYTE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 56649124727     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0440-0     Document Type: Article

References (31)

1. C Adida C Haioun P Gaulard E Lepage P Morel J Briere 2000 Prognostic significance of survivin expression in diffuse large B-cell lymphomas Blood 96 1921 1925
2. DA Cantrell KA Smith 1983 Transient expression of interleukin 2 receptors. Consequences for T cell growth J Exp Med 158 1895 1911 10.1084/jem.158.6.1895
3. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244 1253
4. A Gallamini C Stelitano R Calvi M Bellei D Mattei U Vitolo F Morabito M Martelli E Brusamolino E Iannitto F Zaja S Cortelazzo L Rigacci L Devizzi G Todeschini G Santini M Brugiatelli M Federico 2004 Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood 103 2474 2479 10.1182/blood-2003-09-3080
5. C Gisselbrecht P Gaulard E Lepage B Coiffier J Brière C Haioun 1998 Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA) Blood 92 76 82
6. H Goto H Tsurumi M Takemura Y Ino-Shimomura S Kasahara M Sawada 2005 Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index J Cancer Res Clin Oncol 131 73 79 10.1007/s00432-004-0600-9
7. N Goto H Tsurumi M Takemura T Hara M Sawada S Kasahara 2006 Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma Eur J Haematol 77 217 225 10.1111/j.1600-0609.2006.00702.x
8. C Haioun E Lepage C Gisselbrecht Y Bastion B Coiffier P Brice 1997 Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 15 1131 1137
9. T Hara H Tsurumi M Takemura H Goto T Yamada M Sawada 2000 Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma Am J Hematol 64 257 261 10.1002/1096-8652(200008)64: 4<257::AID-AJH4>3.0.CO;2-2
10. NL Harris ES Jaffe J Diebold G Flandrin HK Muller-Hermelink J Vardiman 1999 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol 17 3835 3849
11. A Ichikawa T Kinoshita T Watanabe H Kato H Nagai K Tsushita 1997 Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma N Engl J Med 337 529 534 10.1056/NEJM199708213370804
12. E Legouffe C Rodriguez MC Picot B Richard B Klein JF Rossi 1998 C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma Leuk Lymphoma 31 351 357
13. AA Miller E Salewski 1994 Prospects for pirarubicin Med Pediatr Oncol 22 261 268 10.1002/mpo.2950220410
14. N Niitsu J Okabe-Kado T Kasukabe Y Yamamoto-Yamaguchi M Umeda Y Honma 1999 Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma Blood 94 3541 3550
15. N Niitsu M Okamoto J Okabe-Kado T Takagi T Yoshida S Aoki 2001 Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma Blood 97 1202 1210 10.1182/blood.V97.5.1202
16. N Niitsu Y Honma K Iijima T Takagi M Higashihara U Sawada 2003 Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma Leukemia 17 196 202 10.1038/sj.leu.2402699
17. K Ogata N Yokose E An K Kamikubo H Tamura K Dan 1996 Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome Br J Haematol 93 45 52 10.1046/j.1365-2141.1996.4641003.x
18. HA Preti F Cabanillas M Talpaz SL Tucker JF Seymour R Kurzrock 1997 Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma Ann Intern Med 127 186 194
19. RJ Robb 1982 Human T-cell growth factor: purification and interaction with a cellular receptor Lymphokine Res 1 37 43
20. LA Rubin CC Kurman ME Fritz WE Biddison B Boutin R Yarchoan 1985 Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro J Immunol 135 3172 3177
21. P Salven L Teerenhovi H Joensuu 1999 A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma Blood 94 3334 3339
22. K Sasaki N Niitsu 2000 Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma Eur J Haematol 65 195 202 10.1034/j.1600-0609.2000.065003195.x
23. M Sawada H Tsurumi T Yamada T Hara K Fukuno H Goto 2002 A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy Eur J Haematol 68 354 361 10.1034/j.1600-0609.2002. 01654.x
24. MA Shipp MD Abeloff KH Antman G Carroll A Hagenbeek M Loeffler 1999 International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury J Clin Oncol 17 423 429
25. R Stasi PL Zinzani P Galieni VM Lauta E Damasio E Dispensa 1994 Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma Br J Haematol 88 770 777 10.1111/j.1365-2141.1994. tb05116.x
26. T Takagi M Oguro 1987 (2″-R)-4′-o- tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies Cancer Chemother Pharmacol 20 151 154 10.1007/BF00253970
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993 A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987 994 10.1056/NEJM199309303291402
28. H Tsurumi T Yamada M Sawada S Kasahara N Kanemura Y Kojima 2004 Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study J Cancer Res Clin Oncol 130 107 113 10.1007/s00432-003-0508-9
29. H Tsurumi T Hara N Goto N Kanemura S Kasahara M Sawada 2007 A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma Hematol Oncol 25 107 114 10.1002/hon.815
30. MA Wasik EC Vonderheid RD Bigler R Marti SR Lessin M Polansky 1996 Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications Arch Dermatol 132 42 47 10.1001/archderm.132.1.42
31. F Zaja D Russo F Silvestri R Fanin D Damiani L Infanti 1997 Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome Haematologica 82 171 177